未找到相关数据
Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.
被引：17
作者：
Goldman, Jonathan Wade
Gandhi, Leena
Patnaik, Amita
Rosen, Lee S.
Hilton, John Frederick
Papadopoulos, Kyriakos P.
Tolaney, Sara M.
Beeram, Muralidhar
Rasco, Drew Warren
Myrand, Scott P.
Beckmann, Richard P.
Kulanthaivel, Palaniappan
Frenzel, Martin
Cronier, Damien
Chan, Edward M.
Flaherty, Keith
Wen, Patrick Y.
Tolcher, Anthony W.
Shapiro, Geoffrey
机构：
[1] Univ Calif Los Angeles, Santa Monica Hematol Oncol, Santa Monica, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] START Ctr Canc Care, San Antonio, TX USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[6] Dana Farber Canc Ctr Inst, Boston, MA USA
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8026
引用
收藏
页数：1
相关论文